###begin article-title 0
Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers
###end article-title 0
###begin p 1
###xml 34 45 <span type="species:ncbi:205488">Ebola virus</span>
###xml 47 51 <span type="species:ncbi:205488">EBOV</span>
###xml 171 177 <span type="species:ncbi:9606">humans</span>
###xml 264 268 <span type="species:ncbi:205488">EBOV</span>
###xml 448 452 <span type="species:ncbi:205488">EBOV</span>
###xml 544 548 <span type="species:ncbi:205488">EBOV</span>
###xml 806 821 <span type="species:ncbi:9544">rhesus macaques</span>
###xml 834 838 <span type="species:ncbi:205488">EBOV</span>
The filoviruses Marburg virus and Ebola virus (EBOV) quickly outpace host immune responses and cause hemorrhagic fever, resulting in case fatality rates as high as 90% in humans and nearly 100% in nonhuman primates. The development of an effective therapeutic for EBOV is a daunting public health challenge and is hampered by a paucity of knowledge regarding filovirus pathogenesis. This report describes a successful strategy for interfering with EBOV infection using antisense phosphorodiamidate morpholino oligomers (PMOs). A combination of EBOV-specific PMOs targeting sequences of viral mRNAs for the viral proteins (VPs) VP24, VP35, and RNA polymerase L protected rodents in both pre- and post-exposure therapeutic regimens. In a prophylactic proof-of-principal trial, the PMOs also protected 75% of rhesus macaques from lethal EBOV infection. The work described here may contribute to development of designer, "druggable" countermeasures for filoviruses and other microbial pathogens.
###end p 1
###begin title 2
Synopsis
###end title 2
###begin p 3
###xml 0 11 <span type="species:ncbi:205488">Ebola virus</span>
###xml 13 17 <span type="species:ncbi:205488">EBOV</span>
###xml 103 109 <span type="species:ncbi:9606">humans</span>
###xml 178 182 <span type="species:ncbi:205488">EBOV</span>
###xml 483 487 <span type="species:ncbi:205488">EBOV</span>
###xml 848 852 <span type="species:ncbi:205488">EBOV</span>
###xml 931 935 <span type="species:ncbi:205488">EBOV</span>
###xml 1022 1037 <span type="species:ncbi:9544">rhesus macaques</span>
###xml 1050 1054 <span type="species:ncbi:205488">EBOV</span>
Ebola virus (EBOV) causes a highly lethal hemorrhagic fever that results in up to 50%-90% mortality in humans. There are currently no available vaccines or therapeutics to treat EBOV infection. To date, multiple pre- and post-exposure therapeutic strategies, primarily focused on bolstering the host immune response or inhibiting viral replication, have been undertaken with limited success. Here, Bavari and colleagues report the development of a successful therapeutic regimen for EBOV infection based on antisense phosphorodiamidate morpholino oligomers (PMOs). PMOs are a subclass of chemically modified antisense oligonucleotides that interfere with the translation of viral mRNA, thus inhibiting viral amplification. Using a cell-free translation system, a cell-based assay, and survival studies in rodents, we identified several efficacious EBOV-specific PMOs. Further, prophylactic administration of a combination of three EBOV-specific PMOs specifically targeting VP24, VP35, and the viral polymerase L protected rhesus macaques from lethal EBOV infection. This is the first successful antiviral intervention against filoviruses in nonhuman primates. These findings may serve as the basis for a new strategy to quickly develop virus-specific therapies in defense against known, emerging, and genetically engineered bioterrorism threats.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 180 181 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b001">1</xref>
###xml 182 183 182 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b002">2</xref>
###xml 271 272 271 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b003">3</xref>
###xml 273 274 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b006">6</xref>
###xml 618 619 618 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b007">7</xref>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b010">10</xref>
###xml 923 925 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b011">11</xref>
###xml 64 75 <span type="species:ncbi:205488">Ebola virus</span>
###xml 77 81 <span type="species:ncbi:205488">EBOV</span>
###xml 515 519 <span type="species:ncbi:205488">EBOV</span>
The development of effective countermeasures to the filoviruses Ebola virus (EBOV) and Marburg virus (MARV) has been a long-sought and difficult endeavor, yielding little success [1,2]. Although the worst outbreaks have resulted in only several hundred deaths worldwide [3-6], the filoviruses are considered a significant global health threat, because as the reservoir remains unknown, the pathogen is extremely deadly and highly infectious by aerosol, and there is anecdotal evidence that the use of both MARV and EBOV were explored as potential biowarfare agents in the offensive program of the former Soviet Union [7-10]. The filoviruses are relatively simple viruses of 19-Kb genomes and consist of seven genes which encode nucleoprotein (NP), glycoprotein, four smaller viral proteins (VPs) (VP24, VP30, VP35, and VP40), and the RNA-dependent RNA polymerase (L protein), all in a single strand of negative-sensed RNA [11].
###end p 5
###begin p 6
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b001">1</xref>
###xml 250 251 250 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b002">2</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b012">12</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b013">13</xref>
###xml 718 719 718 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b001">1</xref>
###xml 720 722 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b014">14</xref>
###xml 723 725 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b015">15</xref>
###xml 906 908 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b016">16</xref>
###xml 46 50 <span type="species:ncbi:205488">EBOV</span>
###xml 207 211 <span type="species:ncbi:205488">EBOV</span>
###xml 384 388 <span type="species:ncbi:205488">EBOV</span>
###xml 464 468 <span type="species:ncbi:205488">EBOV</span>
###xml 646 650 <span type="species:ncbi:205488">EBOV</span>
###xml 685 689 <span type="species:ncbi:205488">EBOV</span>
###xml 728 732 <span type="species:ncbi:205488">EBOV</span>
###xml 890 904 <span type="species:ncbi:9544">rhesus monkeys</span>
The development of an effective treatment for EBOV is hindered by lack of a clear understanding of filovirus pathogenesis, disparity between animal models, and both the difficulty and danger of working with EBOV under biosafety-level-4 conditions [1,2]. Although there has been significant progress toward vaccine development via demonstration of protection in nonhuman primates from EBOV illness and death [12,13], a vaccine will not fulfill all requirements for EBOV countermeasures. Administration of type I interferons, therapeutic vaccines, immune globulins, ribavirin, and other nucleoside analogues have been somewhat successful in rodent EBOV models, but all failed to benefit EBOV-infected nonhuman primates [1,14,15]. EBOV frequently causes severe disseminated intravascular coagulation, and administration of a recombinant clotting inhibitor was recently shown to protect 33% of rhesus monkeys [16]. It appears that host-directed consequence management of the disease alone may not be sufficient, and an additional well-orchestrated sequence-specific attack on viral replication may be more effective as a successful anti-filovirus treatment regimen.
###end p 6
###begin p 7
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b017">17</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b018">18</xref>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b019">19</xref>
###xml 623 625 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b020">20</xref>
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b021">21</xref>
###xml 748 750 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b022">22</xref>
###xml 751 753 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b023">23</xref>
###xml 819 821 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b024">24</xref>
###xml 838 840 838 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b023">23</xref>
###xml 841 843 841 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b025">25</xref>
###xml 872 874 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b026">26</xref>
###xml 854 870 <span type="species:ncbi:227859">SARS coronavirus</span>
The ability of virus-specific antisense oligonucleotides to inhibit viral growth by interfering with translation of viral RNAs was first demonstrated in 1978 [17,18]. Since then, remarkable progress has been made by modifying oligonucleotides to increase their stability, affinity, and delivery into cells [19]. Phosphorodiamidate morpholino oligomers (PMOs) are a subclass of antisense agents modified to include a phosphorodiamidate linkage and morpholine ring, and exhibit limited off-target effects, favorable base stacking, high duplex stability, high solubility, cell permeability, and no hybridization complexities [20,21]. Formation of a PMO:mRNA duplex can effectively block translation of viral RNA, thereby inhibiting viral replication [22,23]. Antisense PMO are effective as antivirals against vesiviruses [24], flaviviruses [23,25], and the SARS coronavirus [26]. The successful inhibition of viral replication by PMOs in these reports was demonstrated in vitro, but has not yet been shown in an animal model.
###end p 7
###begin title 8
Results
###end title 8
###begin title 9
###xml 23 27 <span type="species:ncbi:205488">EBOV</span>
In Vitro Inhibition of EBOV Translation and Replication by Gene-Specific PMOs
###end title 9
###begin p 10
###xml 228 236 228 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g001">Figure 1</xref>
###xml 463 471 463 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g001">Figure 1</xref>
###xml 473 474 473 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g001">1</xref>
###xml 615 623 614 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g001">Figure 1</xref>
###xml 625 626 624 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g001">1</xref>
###xml 984 992 982 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g001">Figure 1</xref>
###xml 1168 1176 1166 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g001">Figure 1</xref>
###xml 95 99 <span type="species:ncbi:205488">EBOV</span>
###xml 204 208 <span type="species:ncbi:205488">EBOV</span>
###xml 246 250 <span type="species:ncbi:205488">EBOV</span>
###xml 390 394 <span type="species:ncbi:205488">EBOV</span>
###xml 580 584 <span type="species:ncbi:205488">EBOV</span>
###xml 655 659 <span type="species:ncbi:205488">EBOV</span>
###xml 863 867 <span type="species:ncbi:205488">EBOV</span>
###xml 956 960 <span type="species:ncbi:205488">EBOV</span>
We hypothesized that PMO inhibition of viral mRNA translation would provide protection against EBOV infections. In order to test our hypothesis, PMOs were designed to inhibit translation of the mRNAs for EBOV VP35, VP24, and L (Figure 1A). These EBOV-specific PMOs demonstrated sequence-specific inhibition when compared with a PMO molecule with a MARV-specific sequence or PMOs containing EBOV-scrambled sequences in a reporter-based in vitro translation assay (Figure 1B-1D). No inhibition was observed for the scrambled or nonspecific PMO at up to 10 muM concentration for the EBOV VP24, VP35, or L RNA targets (Figure 1B-1D). To determine whether the EBOV-specific PMOs could reduce viral propagation in vitro, VeroE6 cells were pretreated with the PMOs at a concentration of 20 muM and then infected with a multiplicity of infection of 1. Treatment with the EBOV VP24-, VP35-, or L-specific PMO was able to consistently reduce the viral titers in the EBOV-infected VeroE6 cells (Figure 1E). A combination of the three PMOs also reduced the viral titers in the VeroE6 cells, but did not show an enhanced effect as compared with treatment with any one of the PMOs (Figure 1E). In the same assay, the viral titers in the scrambled PMO-treated cells were nearly identical to those observed in untreated VeroE6 cells, and the PMOs did not cause obvious cytotoxicity at concentrations used in this assay (unpublished data).
###end p 10
###begin title 11
###xml 0 4 <span type="species:ncbi:205488">EBOV</span>
###xml 50 54 <span type="species:ncbi:205488">EBOV</span>
EBOV-Specific PMOs Protect Rodents against Lethal EBOV Infection
###end title 11
###begin p 12
###xml 435 443 434 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g002">Figure 2</xref>
###xml 445 446 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g002">2</xref>
###xml 449 453 448 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p &lt; </italic>
###xml 683 691 681 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g002">Figure 2</xref>
###xml 694 697 692 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p =</italic>
###xml 884 892 882 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g002">Figure 2</xref>
###xml 894 895 892 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g002">2</xref>
###xml 1183 1191 1181 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g002">Figure 2</xref>
###xml 1194 1197 1192 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p =</italic>
###xml 1501 1509 1498 1506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g002">Figure 2</xref>
###xml 1669 1670 1665 1666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1885 1886 1880 1881 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 2461 2462 2455 2456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 40 44 <span type="species:ncbi:205488">EBOV</span>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 204 209 <span type="species:ncbi:10090">mouse</span>
###xml 218 222 <span type="species:ncbi:205488">EBOV</span>
###xml 289 293 <span type="species:ncbi:205488">EBOV</span>
###xml 388 392 <span type="species:ncbi:10090">mice</span>
###xml 657 661 <span type="species:ncbi:10090">mice</span>
###xml 756 760 <span type="species:ncbi:10090">mice</span>
###xml 793 797 <span type="species:ncbi:10090">mice</span>
###xml 878 882 <span type="species:ncbi:205488">EBOV</span>
###xml 1107 1111 <span type="species:ncbi:205488">EBOV</span>
###xml 1269 1273 <span type="species:ncbi:205488">EBOV</span>
###xml 1295 1299 <span type="species:ncbi:10090">mice</span>
###xml 1330 1334 <span type="species:ncbi:10090">mice</span>
###xml 1406 1410 <span type="species:ncbi:10090">mice</span>
###xml 1485 1489 <span type="species:ncbi:205488">EBOV</span>
###xml 1529 1533 <span type="species:ncbi:205488">EBOV</span>
###xml 1543 1547 <span type="species:ncbi:10090">mice</span>
###xml 1757 1761 <span type="species:ncbi:10090">mice</span>
###xml 1792 1796 <span type="species:ncbi:10090">mice</span>
###xml 1799 1803 <span type="species:ncbi:10090">Mice</span>
###xml 1969 1973 <span type="species:ncbi:10090">mice</span>
###xml 2004 2008 <span type="species:ncbi:10090">mice</span>
###xml 2137 2141 <span type="species:ncbi:205488">EBOV</span>
###xml 2151 2155 <span type="species:ncbi:10090">mice</span>
###xml 2328 2332 <span type="species:ncbi:205488">EBOV</span>
###xml 2516 2520 <span type="species:ncbi:205488">EBOV</span>
To evaluate the in vivo efficacy of the EBOV-specific PMOs, we first determined the survival of mice treated with individual PMOs at 24 h and 4 h before challenge with 1,000 plaque-forming units (pfu) of mouse-adapted EBOV. The three PMOs exhibited a wide range of efficacy against lethal EBOV infection. Both the VP24- and VP35-specific PMOs provided nearly complete protection when the mice were pretreated twice with 500 mug doses (Figure 2A-2B, p < 0.001 for both VP24 and VP35 PMO treatment versus PBS treatment). In contrast, and despite its strong activity in the cell-free translation assay, the L-specific PMO conferred survival to ~30% of treated mice at the 500-mug dose (Figure 2C, p = 0.5 for both doses of the L PMO compared with PBS-treated mice). As expected, treatment of the mice with a Marburg-specific VP24, VP35, or L PMO did not provide protection against EBOV (Figure 2A-2C). Next, we investigated whether a combination of all these PMOs could further enhance efficacy. We found that when the VP24-, VP35-, and L-specific PMOs were administered together at 24 h and 4 h before lethal EBOV challenge, this resulted in robust protection at all the doses tested (Figure 2D, p = 0.00001, 0.001, and 0.0136, respectively, for the 500-, 50-, and 5-mug EBOV-specific PMO-treated mice compared with the PBS-treated mice). To investigate the usefulness of the PMO in a post-exposure regimen, mice were treated with a single dose of the three PMOs administered 24 h after EBOV infection (Figure 2E). The PMO-treated EBOV-infected mice were fully protected at the 500-mug doses, and at lower doses the post-challenge treatment provided enhanced protection (p = 0.00001, 0.0136, and 0.2105, respectively, for the 500-, 50-, and 5-mug PMO-treated mice compared with the PBS-treated mice). Mice receiving a single PMO treatment 4 h before infection showed similar protection (p = 0.00001, 0.237, and 1.0, respectively, for the 500-, 50-, and 5-mug PMO-treated mice compared with the PBS-treated mice). Here, a single dose of PMO at 24 hpi was used and, at the highest concentration, the combination of PMOs completely protected EBOV-infected mice. In this single-dose therapeutic regimen, the lower PMO dosages did not provide complete protection. It may be possible that repeated injections of lower concentrations of EBOV-specific PMOs could provide equivalent protection to fewer administrations of higher amounts. Importantly, multiple injections (n > 5) of nonspecific PMOs did not enhance survival of EBOV-infected rodents (unpublished data).
###end p 12
###begin p 13
###xml 280 288 280 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g003">Figure 3</xref>
###xml 389 397 389 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g003">Figure 3</xref>
###xml 630 638 630 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g003">Figure 3</xref>
###xml 640 641 640 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g003">3</xref>
###xml 841 849 841 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g003">Figure 3</xref>
###xml 851 852 851 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g003">3</xref>
###xml 1251 1259 1251 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g003">Figure 3</xref>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 97 101 <span type="species:ncbi:205488">EBOV</span>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 304 308 <span type="species:ncbi:205488">EBOV</span>
###xml 366 370 <span type="species:ncbi:205488">EBOV</span>
###xml 383 387 <span type="species:ncbi:10090">mice</span>
###xml 433 437 <span type="species:ncbi:205488">EBOV</span>
###xml 485 489 <span type="species:ncbi:205488">EBOV</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
###xml 701 705 <span type="species:ncbi:205488">EBOV</span>
###xml 739 743 <span type="species:ncbi:10090">mice</span>
###xml 783 787 <span type="species:ncbi:10090">mice</span>
###xml 789 793 <span type="species:ncbi:205488">EBOV</span>
###xml 1056 1060 <span type="species:ncbi:10090">mice</span>
Examination of tissues 3 d after infection showed that treatment of mice with the combination of EBOV-specific PMOs slowed viral spread compared to mice treated with the scrambled PMO. Infected cells were easily observed in the spleens of the mice treated with the scrambled PMO (Figure 3A), whereas few EBOV-infected cells could be found in the spleens of the anti-EBOV PMO-treated mice (Figure 3B). By 6 d after viral inoculation, EBOV infection was fulminant in the spleens of both EBOV and scrambled PMO-treated animals (unpublished data) and had spread to the livers of both mice treated with scrambled and combination PMOs (Figure 3C-3D). However, the extent of the infection was limited in the EBOV-specific combination PMO-treated mice, and, unlike the scrambled PMO-treated mice, EBOV antigen was not detectable within hepatocytes (Figure 3C-3D). Viral antigen was not observed in the kidney on day 3; however, on day 6, viral antigen was more readily observed in the kidneys of the scrambled PMO-treated compared with the combination PMO-treated mice (unpublished data). Further, the viral titers in the spleen, liver, and kidney of the PMO-treated, infected animals corroborated the observed pattern of antigen staining within the tissues (Figure 3E).
###end p 13
###begin p 14
###xml 215 216 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 224 225 224 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 312 320 312 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g004">Figure 4</xref>
###xml 549 557 549 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g004">Figure 4</xref>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b015">15</xref>
###xml 829 837 829 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g004">Figure 4</xref>
###xml 840 841 840 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 21 25 <span type="species:ncbi:10090">mice</span>
###xml 78 82 <span type="species:ncbi:205488">EBOV</span>
###xml 105 109 <span type="species:ncbi:205488">EBOV</span>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 255 259 <span type="species:ncbi:205488">EBOV</span>
###xml 375 379 <span type="species:ncbi:205488">EBOV</span>
###xml 470 474 <span type="species:ncbi:10090">mice</span>
###xml 521 532 <span type="species:ncbi:205488">Ebola virus</span>
###xml 641 645 <span type="species:ncbi:10090">mice</span>
###xml 698 702 <span type="species:ncbi:205488">EBOV</span>
###xml 759 763 <span type="species:ncbi:10090">mice</span>
###xml 813 817 <span type="species:ncbi:205488">EBOV</span>
To determine whether mice treated with the PMOs generated immune responses to EBOV, they were tested for EBOV-specific cell-mediated and humoral immune responses. 4 wk after infection, the mice demonstrated both CD4+ and CD8+ T cell responses to multiple EBOV-specific peptides, including NP and VP35 sequences (Figure 4A, unpublished data). They also generated strong serum EBOV-specific antibody responses that were similar to the post-challenge antibody responses of mice protected by a therapeutic vaccine containing Ebola virus-like particles (Figure 4B) [15]. To find out if the generated immune responses were protective, PMO-treated mice were rechallenged with another dose of 1,000 pfu of EBOV 4 wk after surviving the initial challenge, and all the mice were completely protected from the second lethal EBOV infection (Figure 4C, p < 0.000001).
###end p 14
###begin p 15
###xml 229 237 229 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g005">Figure 5</xref>
###xml 338 339 338 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 454 455 454 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 627 635 627 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g005">Figure 5</xref>
###xml 793 794 793 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 60 64 <span type="species:ncbi:205488">EBOV</span>
###xml 91 102 <span type="species:ncbi:10141">guinea pigs</span>
###xml 108 112 <span type="species:ncbi:205488">EBOV</span>
###xml 213 217 <span type="species:ncbi:205488">EBOV</span>
###xml 275 286 <span type="species:ncbi:10141">guinea pigs</span>
###xml 322 326 <span type="species:ncbi:205488">EBOV</span>
###xml 373 384 <span type="species:ncbi:10141">guinea pigs</span>
###xml 402 413 <span type="species:ncbi:10141">guinea pigs</span>
###xml 511 522 <span type="species:ncbi:10141">guinea pigs</span>
###xml 780 791 <span type="species:ncbi:10141">guinea pigs</span>
###xml 1071 1082 <span type="species:ncbi:10141">guinea pigs</span>
To verify the effectiveness of the PMO treatment in another EBOV animal model, we infected guinea pigs with EBOV and treated them with a single dose of the PMO combination either 24 h before or 24 h or 96 h after EBOV infection (Figure 5A). Survival was greatly increased in guinea pigs receiving the treatment 96 h after EBOV infection (p = 0.029, compared with untreated guinea pigs), in contrast to guinea pigs treated 24 h before or after infection (p = 0.5 and 0.227, respectively, compared with untreated guinea pigs). The mean viral titer for each group, measured on 7 dpi, closely mirrored the survival rates observed (Figure 5B). Results of a logistic regression indicated that reduction of the viral titer had a significant effect on the survival outcome of PMO-treated guinea pigs (p = 0.0292). With each log10 reduction in viral titer, there was a 56% decrease in the odds of surviving challenge (odds ratio = 0.434). It remains to be determined if administration of multiple or larger PMO doses might have increased the efficacy of the PMO treatments in the guinea pigs.
###end p 15
###begin title 16
PMO Pretreatment Protects Rhesus Monkeys
###end title 16
###begin p 17
###xml 180 181 180 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 235 236 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 307 315 307 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g006">Figure 6</xref>
###xml 871 879 871 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g006">Figure 6</xref>
###xml 975 983 975 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g006">Figure 6</xref>
###xml 1084 1092 1084 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g006">Figure 6</xref>
###xml 1183 1191 1183 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g006">Figure 6</xref>
###xml 128 142 <span type="species:ncbi:9544">Rhesus monkeys</span>
###xml 260 264 <span type="species:ncbi:205488">EBOV</span>
###xml 425 429 <span type="species:ncbi:10090">mice</span>
###xml 567 571 <span type="species:ncbi:205488">EBOV</span>
###xml 581 596 <span type="species:ncbi:9544">rhesus macaques</span>
###xml 663 678 <span type="species:ncbi:9544">rhesus macaques</span>
###xml 794 798 <span type="species:ncbi:205488">EBOV</span>
###xml 922 926 <span type="species:ncbi:205488">EBOV</span>
###xml 1057 1061 <span type="species:ncbi:205488">EBOV</span>
###xml 1157 1161 <span type="species:ncbi:205488">EBOV</span>
###xml 1286 1290 <span type="species:ncbi:205488">EBOV</span>
Based on the encouraging results both in vitro and in rodents, we designed a small proof-of-concept trial in nonhuman primates. Rhesus monkeys were treated with the VP35 PMO only (n = 4) or a combination of the VP24, VP35, and L PMOs (n = 4) from 2 d prior to EBOV infection through day 9 of the infection (Figure 6A). An initial study tested the efficacy of the VP35 PMO, the compound that exhibited the highest activity in mice. Unfortunately, all of the VP35 PMO-treated monkeys, as well as the untreated control monkey, died within the time-to-death expected for EBOV-infected rhesus macaques (days 7, 7, 8, 8, and 7, respectively). In contrast, treatment of rhesus macaques with a combination of the VP24, VP35, and L PMOs showed substantial efficacy. Two PMO-treated monkeys survived the EBOV challenge with few clinical signs beyond mild depression from days 6-9 (Figure 6B). A third PMO-treated monkey cleared the EBOV infection and remained aviremic from days 9-14 (Figure 6C), but died of a severe bacterial infection, with no evidence of ongoing EBOV infection, on day 16 (Figure 6B, unpublished data). The fourth PMO-treated monkey succumbed to EBOV infection on day 10 (Figure 6B). Three naive control monkeys used in this experiment received no treatment and succumbed to EBOV infection on days 7, 9, and 10. Since the VP35 PMO alone did not provide any protection to nonhuman primates, these data suggest that a combination of PMOs is more efficacious than a single-target PMO treatment and also suggests that protection in the combination PMO-treated monkeys is not due to nonspecific effects of PMO administration.
###end p 17
###begin p 18
###xml 436 444 436 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g006">Figure 6</xref>
###xml 623 631 623 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g006">Figure 6</xref>
###xml 938 946 938 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g006">Figure 6</xref>
###xml 922 926 <span type="species:ncbi:205488">EBOV</span>
We were able to identify only a few early clinical signs or laboratory values that correlated with survival. The laboratory tests that most closely predicted survival were viral titers, platelet counts, and liver-associated enzymes in the blood. The monkeys that did not survive infection had detectable virus by day 5, in stark contrast to the PMO-treated monkeys that survived, which had little to no detectable viremia on days 3-14 (Figure 6C). Both the PMO-treated and naive monkeys exhibited thrombocytopenia, although the PMO-treated monkeys that survived did not have platelet counts much below 100,000 at any time (Figure 6D). Similarly, all the monkeys experienced increases in their liver-associated enzyme levels, including alkaline phosphatase. However, the levels in the surviving monkeys did not climb as high as those that succumbed to the infection and returned to normal levels within the month after the EBOV infection (Figure 6E, unpublished data).
###end p 18
###begin p 19
###xml 132 137 <span type="species:ncbi:9606">Human</span>
###xml 684 688 <span type="species:ncbi:205488">EBOV</span>
###xml 714 728 <span type="species:ncbi:9544">rhesus monkeys</span>
###xml 758 762 <span type="species:ncbi:205488">EBOV</span>
###xml 825 829 <span type="species:ncbi:10090">mice</span>
No correlation was found between survival and multiple other hematological values, body temperature, serum cytokines (measured by a Human 25-plex kit from Biosource, Camarillo, California, United States), or fibrin degradation products (unpublished data). Importantly, PMO administration did not induce early (0-2 dpi) detectable serum IFN, TNF, or other cytokines in the nonhuman primates (unpublished data), indicating that the protection was likely not due to nonspecific effects via induction of innate immunity. Since the surviving PMO-treated monkeys had low to undetectable viremias following infection, we assessed the immune responses of the surviving monkeys. By 28 d after EBOV challenge, the surviving rhesus monkeys had high levels of both anti-EBOV antibodies and T cell responses, similar to the PMO-protected mice (unpublished data).
###end p 19
###begin title 20
Discussion
###end title 20
###begin p 21
###xml 0 4 <span type="species:ncbi:205488">EBOV</span>
###xml 184 188 <span type="species:ncbi:205488">EBOV</span>
###xml 242 246 <span type="species:ncbi:205488">EBOV</span>
###xml 392 396 <span type="species:ncbi:205488">EBOV</span>
EBOV infections represent a significant public health threat, with no reliable effective chemotherapeutics. Our current studies indicate the effectiveness of PMOs targeted to specific EBOV mRNAs against in vitro, rodent, and nonhuman primate EBOV infections. The data presented here are in line with our working hypothesis that a combination of PMOs that target multiple viral genes can slow EBOV replication, allowing enough time for development of antiviral immune responses and viral clearance.
###end p 21
###begin p 22
###xml 1048 1056 1048 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g001">Figure 1</xref>
###xml 44 48 <span type="species:ncbi:205488">EBOV</span>
###xml 92 96 <span type="species:ncbi:205488">EBOV</span>
###xml 188 192 <span type="species:ncbi:205488">EBOV</span>
###xml 340 344 <span type="species:ncbi:205488">EBOV</span>
###xml 467 471 <span type="species:ncbi:205488">EBOV</span>
###xml 532 536 <span type="species:ncbi:205488">EBOV</span>
Cell-free experiments demonstrated that the EBOV-specific PMOs were efficient at inhibiting EBOV mRNA translation and that MARV-specific PMOs had no effect on translation of corresponding EBOV genes. While the reporter-based in vitro assays appeared to be good indicators of sequence-specific activity of PMOs, it seems that in the case of EBOV, the in vitro translation assays were not fully predictive of the rodent efficacy data. Using VeroE6 cells we showed that EBOV replication was moderately suppressed in cells treated with EBOV-specific PMOs. However, no visible difference was observed when comparing the ability of a single PMO and the combination of three PMOs to reduce viral growth. The PMOs used in these studies were not conjugated with peptides that facilitate cellular uptake. We have observed lower cellular uptake of naked PMOs compared with peptide-conjugated PMOs by Vero E6 cells (unpublished data), and this may explain the moderate inhibition observed in the in vitro replication assay. Nonetheless, the data summarized in Figure 1 clearly indicate the feasibility of specific gene targeting by unconjugated PMO and the favorable antiviral activity of these compounds.
###end p 22
###begin p 23
###xml 797 798 797 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b001">1</xref>
###xml 799 800 799 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b009">9</xref>
###xml 404 408 <span type="species:ncbi:205488">EBOV</span>
###xml 443 447 <span type="species:ncbi:10090">mice</span>
###xml 651 659 <span type="species:ncbi:9606">patients</span>
###xml 674 678 <span type="species:ncbi:205488">EBOV</span>
Here, we have presented data demonstrating a therapeutic intervention that interferes with viral replication. We hypothesize that the efficacy of this strategy relies on the ability of PMOs, by reducing viral replication, to create a window of opportunity for the immune system to clear the otherwise lethal infection. This approach does not result in sterile protection, as evidenced by the robust anti-EBOV immune responses in the surviving mice and nonhuman primates, and by the mild clinical signs (thrombocytopenia, liver enzyme elevations, depression, and lethargy) observed in the PMO-treated monkeys. It is likely that successful treatment of patients infected with EBOV will require a multifaceted approach consisting of an antiviral, and therapeutics for symptom and disease management [1,9].
###end p 23
###begin p 24
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b027">27</xref>
###xml 702 704 702 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b029">29</xref>
###xml 67 71 <span type="species:ncbi:205488">EBOV</span>
###xml 563 567 <span type="species:ncbi:205488">EBOV</span>
###xml 836 840 <span type="species:ncbi:205488">EBOV</span>
Post-exposure treatment with PMOs was the most efficacious against EBOV in rodents, and, presumably, this is explained by the pharmacokinetic properties of PMO. Following parenteral injection, PMOs are cleared from the bloodstream within hours, but accumulate and remain within tissues such as spleen and liver for days (unpublished data). By administering PMO after challenge, it is likely that higher concentrations were available in the circulation and tissues during the peak of viral replication. Thus, the PMOs may have been able to reduce amplification of EBOV during this critical timeframe, allowing development of appropriate host immune responses to the otherwise lethal viral infection [27-29]. Since effective treatment seemed to require critical timing of PMO administration, and nonhuman primates are highly sensitive to EBOV infection, we decided to both pretreat and administer daily doses of PMOs after viral challenge in the proof-of-concept nonhuman primate studies. While short-term stability in vivo is an unfavorable property for a potential therapeutic, it should be noted that for a deadly acute infection that has only a short period of treatment in the clinic, repeated administration of a life-saving drug is entirely feasible. Along these lines, future studies may show that the pharmacokinetics of PMO can be enhanced by other modifications or alternative routes of administration or regimen to improve efficacy.
###end p 24
###begin p 25
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b030">30</xref>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b031">31</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b033">33</xref>
###xml 103 107 <span type="species:ncbi:205488">EBOV</span>
###xml 108 113 <span type="species:ncbi:10090">mouse</span>
###xml 194 199 <span type="species:ncbi:10090">mouse</span>
###xml 260 264 <span type="species:ncbi:205488">EBOV</span>
###xml 300 306 <span type="species:ncbi:9606">humans</span>
###xml 520 525 <span type="species:ncbi:10090">mouse</span>
###xml 586 591 <span type="species:ncbi:10090">mouse</span>
In order to corroborate the in vitro data and narrow down the number of antiviral lead candidates, the EBOV mouse model was an obvious choice for testing multiple candidate PMOs [30]. While the mouse model has several differences in pathogenesis compared with EBOV infection of nonhuman primates and humans [31-33], it is widely accepted as an appropriate model for rapid testing of potential antivirals before proceeding to NHP trials. While the differences in the pathology may severely hamper the predictive value of mouse studies using therapeutic strategies that rely on targeting mouse-specific virus-host interaction or the pathologic response by rodents, interventions that target viral replication can be evaluated with a high degree of confidence in this model. Antiviral efficacy in rodents may not always be predictive of efficacy in nonhuman primates, although an antiviral compound that is unsuccessful in rodents will most likely also fail in nonhuman primates, justifying initial screening in rodent models.
###end p 25
###begin p 26
###xml 1062 1064 1062 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b034">34</xref>
###xml 171 175 <span type="species:ncbi:205488">EBOV</span>
###xml 528 532 <span type="species:ncbi:205488">EBOV</span>
###xml 981 986 <span type="species:ncbi:9606">human</span>
###xml 1054 1060 <span type="species:ncbi:9606">humans</span>
We have initiated a drug-discovery strategy to identify "druggable," efficacious anti-filovirus PMOs. This proof-of-principle study using PMOs demonstrates favorable anti-EBOV activity both in vitro and in vivo; thus, these molecules represent a pool of potential lead compounds for further evaluation and optimization. Future studies will focus on determining the most favorable PMO dose and regimen and also the therapeutic potential of these molecules. Additionally, antisense PMO designed to target other regions within the EBOV genome will be pursued. Genetically designed microbial therapeutics, such as antisense PMOs or other sequence-based approaches, allow quick hit-to-lead optimization and may accelerate time-to-drug development. Together, these strategies could result in a highly efficacious therapeutic treatment regimen for lethal viral infections. Nucleotide-based antivirals, such as PMOs, can be easily produced in large quantities, have already been tested in human clinical trials, and have appropriate safety profiles for use with humans [34]. The results presented here have far-reaching implications for the treatment of highly lethal hemorrhagic fever viruses, and for diseases caused by many other acute viral diseases including SARS, influenza, and dengue, or other emerging pathogens.
###end p 26
###begin title 27
Materials and Methods
###end title 27
###begin title 28
PMOs.
###end title 28
###begin p 29
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b035">35</xref>
###xml 98 102 <span type="species:ncbi:205488">EBOV</span>
###xml 138 142 <span type="species:ncbi:205488">EBOV</span>
###xml 181 185 <span type="species:ncbi:205488">EBOV</span>
PMOs were designed with sequence homology near or overlapping the AUG translational start site of EBOV VP35 (5'-CCTGCCCTTTGTTCTAGTTG-3'), EBOV VP24 (5'-GCCATGGTTTTTTCTCAGG-3'), and EBOV L (5'-TGGGTATGTTGTGTAGCCAT-3'). Similarly, PMOs were designed with sequence homology near or overlapping the AUG start site of MARV VP35 (5'-GTCCCACATTGTGAAAATTAT-3'), MARV VP24 (5'-CGTTGATAATTCTGCCATG-3'), and MARV L (5'-GATATTGAGTTGGATGCTGCAT-3'). Either the MARV-specific PMOs or an unrelated, "scrambled" PMO (5'-AGTCTCGACTTGCTACCTCA-3') were used as controls in these experiments. The PMOs were synthesized by AVI BioPharma, (Corvallis, Oregon, United States), as previously described [35].
###end p 29
###begin title 30
In vitro translation assay.
###end title 30
###begin p 31
###xml 857 859 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b036">36</xref>
###xml 247 251 <span type="species:ncbi:205488">EBOV</span>
###xml 291 295 <span type="species:ncbi:205488">EBOV</span>
###xml 337 341 <span type="species:ncbi:205488">EBOV</span>
The protein coding sequence for firefly luciferase, without the initiator-Met codon ATG, was subcloned into the multiple cloning site of plasmid pCiNeo (Promega, Madison, Wisconsin, United States). Subsequently, complementary oligonucleotides for EBOV VP35 (-98 to +39; bases 3020 to 3157), EBOV VP24 (-84 to +43; bases 10261 to 10390), EBOV L (-80 to +49; bases 11501 to 11632) were duplexed and subcloned into Nhe 1 and Sal 1 sites. The single AUG in each viral sequence leader is in frame with the coding sequence of luciferase. The plasmids were linearized with Not I, and in vitro transcribed RNA was produced using the T7 polymerase-based Megascript kit and protocol (Ambion, Austin, Texas, United States). In vitro translations were carried out by programming reactions with transcribed RNA at a final concentration of 1 nM, as previously described [36]. The average light units produced by the set of reactions for each treatment were normalized to the mean of all water-only control reactions and expressed as relative light units as compared to the luciferase signal of control reactions.
###end p 31
###begin title 32
In vitro assessment of viral replication in the presence of PMOs.
###end title 32
###begin p 33
###xml 783 785 779 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b037">37</xref>
###xml 178 182 <span type="species:ncbi:9913">calf</span>
###xml 378 382 <span type="species:ncbi:205488">EBOV</span>
###xml 647 651 <span type="species:ncbi:9913">calf</span>
Vero E6 cells were grown to confluency in a 24-well plate. On day 0, the indicated PMOs were added in 100 mul of serum-free EMEM. After 2 h, 900 mul of EMEM containing 10% fetal calf serum was added for a final concentration of 20 muM of the VP24, VP35, L, or a combination of all three PMOs. On day 1, the medium was removed from the cells and one multiplicity of infection of EBOV-Zaire was added to each well in 100 mul of serum-free EMEM. After 1 h, the viral inoculum was removed and the cells washed twice with PBS. The PMOs were reintroduced for 2 hs in serum-free EMEM and then brought up to a total of 1 ml with EMEM containing 10% fetal calf serum. Supernatant was removed from the cells at 24, 48, or 72 hpi, and the viral titers were determined by standard plaque assay [37].
###end p 33
###begin title 34
Animals.
###end title 34
###begin p 35
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b030">30</xref>
###xml 1019 1021 1019 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b015">15</xref>
###xml 1126 1128 1126 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b030">30</xref>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 180 184 <span type="species:ncbi:10090">Mice</span>
###xml 271 275 <span type="species:ncbi:10090">Mice</span>
###xml 340 345 <span type="species:ncbi:10090">mouse</span>
###xml 354 358 <span type="species:ncbi:205488">EBOV</span>
###xml 432 436 <span type="species:ncbi:10090">mice</span>
###xml 478 482 <span type="species:ncbi:205488">EBOV</span>
###xml 539 543 <span type="species:ncbi:205488">EBOV</span>
###xml 771 782 <span type="species:ncbi:205488">Ebola virus</span>
###xml 841 845 <span type="species:ncbi:10090">mice</span>
###xml 858 862 <span type="species:ncbi:205488">EBOV</span>
###xml 947 951 <span type="species:ncbi:10090">mice</span>
###xml 1003 1007 <span type="species:ncbi:205488">EBOV</span>
###xml 1032 1036 <span type="species:ncbi:10090">mice</span>
###xml 1106 1111 <span type="species:ncbi:10090">mouse</span>
###xml 1120 1124 <span type="species:ncbi:205488">EBOV</span>
C57BL/6 mice, aged 8-10 wk, of both sexes, were obtained from the National Cancer Institute, Frederick Cancer Research and Development Center (Frederick, Maryland, United States). Mice were housed in microisolator cages and provided autoclaved water and chow ad libitum. Mice were challenged by intraperitoneal injection with ~1,000 pfu of mouse-adapted EBOV diluted in phosphate buffered saline (PBS) [30]. Unless otherwise noted, mice were treated 2x at 24 h and 4 h prior to EBOV challenge with 0.5 mg, 0.05, or 0.005 mg of each of the EBOV or MARV VP24, VP35, and L PMOs, a combination of PMOs, or an unrelated PMO. In one presented study, the PMOs (0.5, 0.05, or 0.005 mg) were administered in a single dose 4 h before or 24 h after challenge. Previously, we showed Ebola virus-like particles given 24 h before viral challenge protects mice from lethal EBOV infection. Therefore, for comparison of post-challenge immune responses, a group of mice was injected with virus-like particles 24 h before EBOV challenge [15]. C57BL/6 mice were challenged intraperitoneally with 1,000 plaque-forming units of mouse-adapted EBOV [30].
###end p 35
###begin p 36
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b038">38</xref>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b037">37</xref>
###xml 15 26 <span type="species:ncbi:10141">guinea pigs</span>
###xml 289 300 <span type="species:ncbi:10141">guinea pigs</span>
###xml 483 493 <span type="species:ncbi:10141">guinea-pig</span>
###xml 502 506 <span type="species:ncbi:205488">EBOV</span>
###xml 527 538 <span type="species:ncbi:10141">guinea pigs</span>
Female Hartley guinea pigs, 400-500 g in weight, were obtained from Charles River Laboratories (Wilmington, Massachusetts, United States) and quarantined at the US Army Research Institute for Infectious Diseases for at least 72 h before manipulations. To determine efficacy of the PMOs in guinea pigs, the animals were treated intraperitoneally with a single 10-mg dose of each of the VP24, VP35, and L PMOs 24 h before or 24 h or 96 h after subcutaneous challenge with 1,000 pfu of guinea-pig adapted EBOV [38]. On day 7, the guinea pigs were bled from the retro-orbital sinus and the plasma samples were assessed for viral titers by plaque assay [37].
###end p 36
###begin p 37
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b014">14</xref>
###xml 280 288 280 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0020001-g006">Figure 6</xref>
###xml 7 22 <span type="species:ncbi:9544">rhesus macaques</span>
###xml 78 82 <span type="species:ncbi:205488">EBOV</span>
###xml 480 483 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
Female rhesus macaques of 3-4 kg in weight were challenged with ~1,000 pfu of EBOV-Zaire (1995 strain) [14] by intramuscular injection following PMO treatment. The monkeys were treated from days -2 through day 9 via a combination of parenteral routes (for treatment schedule, see Figure 6). The dose of the VP24 PMO was 12.5-25 mg at each injection, and the dose of the VP35 and L PMOs ranged from 12.5-100 mg per injection. All the monkeys in this study were found to be STLV-1, SIV-, and Herpes B-negative in testing prior to initiation of the study. Monkeys 1496 and 1510 both presented with redness in and bleeding from their vaginal area on days 3-5 post infection. The estrus status of the other monkeys in this study was unknown, although they did not present with vaginal bleeding throughout the 35 d that they were monitored during this study.
###end p 37
###begin p 38
###xml 639 687 639 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Guide for the Care and Use of Laboratory Animals</italic>
###xml 247 251 <span type="species:ncbi:205488">EBOV</span>
The number of animals in each group was determined with the help of a statistician in order to use the least number of animals possible yet still to have the statistical power necessary to allow meaningful interpretation of the data produced. All EBOV-infected animals were handled under maximum containment in a biosafety-level-4 laboratory at the US Army Medical Research Institute for Infectious Diseases. Research was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adhered to principles stated in the National Research Council's Guide for the Care and Use of Laboratory Animals (1996). The facility where this research was conducted is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.
###end p 38
###begin title 39
Hematologic and pathologic sampling.
###end title 39
###begin p 40
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b037">37</xref>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b016">16</xref>
###xml 69 73 <span type="species:ncbi:10090">mice</span>
###xml 317 321 <span type="species:ncbi:205488">EBOV</span>
###xml 374 378 <span type="species:ncbi:10090">mice</span>
###xml 784 788 <span type="species:ncbi:205488">EBOV</span>
Blood samples were obtained under anesthesia by cardiac puncture for mice and from the femoral vein of monkeys. Viremia was assayed by traditional plaque assay [37]. Hematological, cytokine, and D dimer levels, as well as liver-associated enzymes, were measured as previously described [16]. On day 3 and day 6 after EBOV infection, gross necropsies were performed on three mice from each group pretreated with either the combination of PMOs or the "scrambled" PMO. The tissues were collected in 10% neutral buffered formalin and held in the biosafety-level-4 laboratory for a minimum of 30 d. The tissues were then decontaminated, embedded in paraffin, and sectioned for histology. The sections were then stained with hematoxylin and eosin for routine light microscopy or exposed to EBOV-specific antisera to identify viral antigen within the tissue samples.
###end p 40
###begin title 41
###xml 27 31 <span type="species:ncbi:205488">EBOV</span>
Immune responses following EBOV infection.
###end title 41
###begin p 42
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b039">39</xref>
###xml 348 349 346 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 357 358 355 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 426 428 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0020001-b040">40</xref>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
###xml 81 85 <span type="species:ncbi:205488">EBOV</span>
###xml 107 111 <span type="species:ncbi:205488">EBOV</span>
###xml 380 384 <span type="species:ncbi:10090">mice</span>
###xml 440 444 <span type="species:ncbi:205488">EBOV</span>
###xml 579 583 <span type="species:ncbi:205488">EBOV</span>
Blood was collected from the surviving mice or monkeys, respectively, 28 d after EBOV challenge. Levels of EBOV-specific antibodies were determined from serum or plasma samples, as previously described [39]. Antibody titers were defined as the reciprocal of the highest dilution giving a net optical density value >/=0.2. Epitopes recognized by CD4+ and CD8+ T cells of surviving mice were determined as previously described [40]. Briefly, EBOV-specific responses were analyzed by culturing splenocytes with 1-5 mug overlapping 15-residue peptides representing the GP or VP40 of EBOV (Mimotopes, Clayton, Victoria, Australia) or 25 ng/ml phorbol 12-myristate 13-acetate and 1.25 mug/ml ionomycin in complete RPMI containing 10 mug/ml brefeldin A. After 5 h of culture, the cells were stained with anti-CD44, -CD8, or -CD4 (Pharmingen, San Diego, California, United States) in brefeldin A. After the cell surface staining, the cells were fixed in 1% formaldehyde, permeabilized with saponin, and stained with anti-IFN-gamma PE (Pharmingen).
###end p 42
###begin title 43
Statistical analysis.
###end title 43
###begin p 44
###xml 305 306 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 128 138 <span type="species:ncbi:10141">guinea pig</span>
To compare the survival rates in the rodent experiments, we used a Fisher exact test with stepdown bootstrap adjustment. In the guinea pig experiments, the viral titers were analyzed by ANOVA with post hoc Dunnett's test, and the effect of viral titers on survival were analyzed by logistic regression. A p value of </=0.05 was considered significant.
###end p 44
###begin p 45
###xml 226 230 <span type="species:ncbi:4530">Rice</span>
KLW and DLS were each the recipient of a National Research Council fellowship award. The authors would like to thank R. Bakken, D. Negley, J. Geisbert, J. Smith, D. Reed, S. VanTongeren, M. Ait Ichou, N. Posten, M. Bailey, C. Rice, and J. Stockman for excellent technical assistance, S. Norris for help with the statistical analysis, and C. S. Gamble, M. K. Hart, and A. L. Schmaljohn for support and helpful discussions. The research described herein was sponsored by the Defense Threat Reduction Agency JSTO-CBD # F_X012_04_RD_B and the Medical Research and Material Command Research Plan as # 03-4-7J-021. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the US Army.
###end p 45
###begin title 46
Abbreviations
###end title 46
###begin p 47
###xml 0 11 <span type="species:ncbi:205488">Ebola virus</span>
Ebola virus
###end p 47
###begin p 48
Marburg virus
###end p 48
###begin p 49
nucleoprotein
###end p 49
###begin p 50
plaque-forming units
###end p 50
###begin p 51
antisense phosphorodiamidate morpholino oligomer
###end p 51
###begin p 52
viral protein
###end p 52
###begin title 53
References
###end title 53
###begin article-title 54
###xml 0 11 <span type="species:ncbi:205488">Ebola virus</span>
Ebola virus: New insights into disease aetiopathology and possible therapeutic interventions
###end article-title 54
###begin article-title 55
The evolving field of biodefence: Therapeutic developments and diagnostics
###end article-title 55
###begin article-title 56
Towards a Vaccine against Ebola Virus
###end article-title 56
###begin article-title 57

###end article-title 57
###begin article-title 58

###end article-title 58
###begin article-title 59
Defense against filoviruses used as biological weapons
###end article-title 59
###begin article-title 60
Marburg and Ebola viruses as aerosol threats
###end article-title 60
###begin article-title 61
Hemorrhagic fever viruses as biological weapons: Medical and public health management
###end article-title 61
###begin article-title 62
Classification, structure, and replication of filoviruses
###end article-title 62
###begin article-title 63
###xml 28 39 <span type="species:ncbi:205488">Ebola virus</span>
###xml 66 71 <span type="species:ncbi:9606">human</span>
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
###end article-title 63
###begin article-title 64
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
###end article-title 64
###begin article-title 65
###xml 95 106 <span type="species:ncbi:205488">Ebola virus</span>
Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections
###end article-title 65
###begin article-title 66
###xml 65 76 <span type="species:ncbi:205488">ebola virus</span>
Role of natural killer cells in innate protection against lethal ebola virus infection
###end article-title 66
###begin article-title 67
###xml 13 24 <span type="species:ncbi:205488">Ebola virus</span>
###xml 105 119 <span type="species:ncbi:9544">rhesus monkeys</span>
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: A study in rhesus monkeys
###end article-title 67
###begin article-title 68
###xml 14 32 <span type="species:ncbi:11886">Rous sarcoma virus</span>
Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide
###end article-title 68
###begin article-title 69
Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide
###end article-title 69
###begin article-title 70
Antisense technologies. Improvement through novel chemical modifications
###end article-title 70
###begin article-title 71
Phosphorodiamidate morpholino oligomers: Favorable properties for sequence-specific gene inactivation
###end article-title 71
###begin article-title 72
Phosphorodiamidate Morpholino Oligomers
###end article-title 72
###begin article-title 73
Evaluation of antisense mechanisms of action
###end article-title 73
###begin article-title 74
Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication
###end article-title 74
###begin article-title 75
Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers
###end article-title 75
###begin article-title 76
###xml 14 26 <span type="species:ncbi:12637">dengue virus</span>
Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers
###end article-title 76
###begin article-title 77
###xml 45 90 <span type="species:ncbi:227859">severe acute respiratory syndrome coronavirus</span>
Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers
###end article-title 77
###begin article-title 78
###xml 26 37 <span type="species:ncbi:205488">Ebola virus</span>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Inflammatory responses in Ebola virus-infected patients
###end article-title 78
###begin article-title 79
###xml 36 41 <span type="species:ncbi:9606">human</span>
Early immune responses accompanying human asymptomatic Ebola infections
###end article-title 79
###begin article-title 80
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human asymptomatic Ebola infection and strong inflammatory response
###end article-title 80
###begin article-title 81
###xml 2 7 <span type="species:ncbi:10090">mouse</span>
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever
###end article-title 81
###begin article-title 82
###xml 67 71 <span type="species:ncbi:10090">mice</span>
Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice
###end article-title 82
###begin article-title 83
Pathogenesis of Ebola Hemorrhagic Fever in Cynomolgus Macaques: Evidence that Dendritic Cells Are Early and Sustained Targets of Infection
###end article-title 83
###begin article-title 84
Vaccine research efforts for filoviruses
###end article-title 84
###begin article-title 85
Redirection of drug metabolism using antisense technology
###end article-title 85
###begin article-title 86
Morpholino antisense oligomers: Design, preparation, and properties
###end article-title 86
###begin article-title 87
Antisense morpholino-oligomers directed against the 5' end of the genome inhibit coronavirus proliferation and growth
###end article-title 87
###begin article-title 88
###xml 17 28 <span type="species:ncbi:205488">Ebola virus</span>
Plaque assay for Ebola virus
###end article-title 88
###begin article-title 89
###xml 29 40 <span type="species:ncbi:205488">Ebola virus</span>
###xml 54 65 <span type="species:ncbi:10141">guinea pigs</span>
Pathogenesis of experimental Ebola virus infection in guinea pigs
###end article-title 89
###begin article-title 90
###xml 0 11 <span type="species:ncbi:205488">Ebola virus</span>
###xml 47 58 <span type="species:ncbi:205488">Ebola virus</span>
Ebola virus-like particles protect from lethal Ebola virus infection
###end article-title 90
###begin article-title 91
###xml 28 29 28 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Induction of Humoral and CD8+ T Cell Responses Are Required for Protection against Lethal Ebola Virus Infection
###end article-title 91
###begin title 92
Figures and Tables
###end title 92
###begin title 93
Gene-Specific PMOs Inhibit Ebola Virus Gene Translation and Growth
###end title 93
###begin p 94
###xml 29 33 <span type="species:ncbi:205488">EBOV</span>
(A) Schematic diagram of the EBOV genome showing the PMO sequences and the relative locations of their mRNA targets.
###end p 94
###begin p 95
###xml 38 42 <span type="species:ncbi:205488">EBOV</span>
###xml 192 196 <span type="species:ncbi:205488">EBOV</span>
###xml 419 423 <span type="species:ncbi:205488">EBOV</span>
(B-D) Sequence-specific inhibition of EBOV VP24 (B), VP35 (C), and L (D) gene targets in cell-free translation assay. Plasmids containing 150 nucleotides encompassing the PMO target area from EBOV VP24, VP35, or L fused to firefly luciferase were used to generate RNA. Inhibition of the VP24, VP35, or L RNA targets was assessed using in vitro translation reactions containing different concentrations of PMO targeting EBOV (*) or MARV (blacksquare, square, filled) VP24, VP35, or L, respectively, or a scrambled (black triangle) PMO, along with the respective RNA. The data are shown as means of three replicates per data point and the standard error of the mean.
###end p 95
###begin p 96
###xml 110 114 <span type="species:ncbi:205488">EBOV</span>
###xml 141 145 <span type="species:ncbi:205488">EBOV</span>
###xml 171 175 <span type="species:ncbi:205488">EBOV</span>
###xml 226 230 <span type="species:ncbi:205488">EBOV</span>
###xml 310 314 <span type="species:ncbi:205488">EBOV</span>
###xml 472 476 <span type="species:ncbi:205488">EBOV</span>
(E) Inhibition of viral amplification by PMOs in vitro. Vero E6 cells were pretreated for 24 h with 20 muM of EBOV VP24-specific PMO (blue), EBOV VP35-specific PMO (red), EBOV L-specific PMO (yellow), combination of the three EBOV-specific PMOs (gray), or a scrambled PMO (black). The cells were infected with EBOV-Zaire (multiplicity of infection = 1), and the viral titers were assessed at 24, 48, and 72 h post infection. The data are presented as percent reduction of EBOV-specific PMO-treated cells, as compared with the scrambled PMO-treated cells (titers at 24 h were 127 pfu/ml, at 48 h were 4,241 pfu/ml, and at 72 h were 202,000 pfu/ml). The experiments were performed at least three times and a single representative experiment is shown.
###end p 96
###begin title 97
###xml 28 32 <span type="species:ncbi:10090">Mice</span>
Ebola-Specific PMOs Protect Mice from Lethal Ebola Virus Infection
###end title 97
###begin p 98
###xml 24 25 24 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 66 70 <span type="species:ncbi:205488">EBOV</span>
###xml 144 148 <span type="species:ncbi:205488">EBOV</span>
(A-C) Survival of mice (n = 10) pretreated at 4 h and 24 h before EBOV infection with 500 (square) or 50 (triangle) mug doses of PMOs targeting EBOV- (filled) or MARV-specific (unfilled) VP24 (A), VP35 (B), L (C), or with PBS (x).
###end p 98
###begin p 99
###xml 22 23 22 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 16 20 <span type="species:ncbi:10090">mice</span>
###xml 64 68 <span type="species:ncbi:205488">EBOV</span>
###xml 169 173 <span type="species:ncbi:205488">EBOV</span>
(D) Survival of mice (n = 10) pretreated at 24 h and 4 h before EBOV infection with 500 mug (square), 50 mug (triangle), or 5 mug (circle) doses of a combination of the EBOV- (filled) or MARV-specific (unfilled) VP24, VP35, and L PMOs or PBS (x).
###end p 99
###begin p 100
###xml 22 23 22 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 16 20 <span type="species:ncbi:10090">mice</span>
###xml 83 87 <span type="species:ncbi:205488">EBOV</span>
###xml 180 184 <span type="species:ncbi:205488">EBOV</span>
(E) Survival of mice (n = 10) treated 4 h before (unfilled) or 24 h after (filled) EBOV infection with 500 mug (square), 50 mug (triangle), or 5 mug (circle) of the combination of EBOV-specific PMOs or an unrelated sequence (x). All the animals in these studies were monitored for at least 28 d for illness, and there were no differences observed in survival within any of the groups between 14 d and 28 d.
###end p 100
###begin title 101
###xml 41 45 <span type="species:ncbi:10090">Mice</span>
PMO Treatment Slows Viral Replication in Mice
###end title 101
###begin p 102
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 88 92 <span type="species:ncbi:205488">EBOV</span>
###xml 240 245 <span type="species:ncbi:10090">mouse</span>
###xml 284 288 <span type="species:ncbi:205488">EBOV</span>
###xml 326 330 <span type="species:ncbi:205488">EBOV</span>
###xml 417 421 <span type="species:ncbi:10090">mice</span>
###xml 438 442 <span type="species:ncbi:205488">EBOV</span>
###xml 500 504 <span type="species:ncbi:10090">mice</span>
(A-D) C57BL/6 mice were challenged intraperitoneally with 1,000 plaque-forming units of EBOV following treatment with PMOs. Immunoperoxidase stain showing presence of viral antigen is brown with hematoxylin counterstain. Spleen (100x) of a mouse treated with scrambled PMO (A) or the EBOV VP24, VP35, and L PMOs (B) 3 d after EBOV infection. Diffuse staining pattern in the livers (600x) of the scrambled PMO-treated mice (C) on day 6 of EBOV infection, compared with focal areas of infection in the mice treated with the combination of PMOs (D).
###end p 102
###begin p 103
###xml 33 37 <span type="species:ncbi:10090">mice</span>
###xml 105 109 <span type="species:ncbi:205488">EBOV</span>
###xml 315 319 <span type="species:ncbi:10090">mice</span>
(E) Viral titers in tissues from mice treated with a combination of 3 PMO and infected with 1,000 pfu of EBOV. Samples of the liver, spleen, and kidney were taken at 3 d or 6 d post challenge (dpc), macerated, and analyzed for viral titer using plaque assay. The data are presented as the mean viral titer of three mice with errors bars representing the standard deviation.
###end p 103
###begin title 104
###xml 32 36 <span type="species:ncbi:10090">Mice</span>
Immune Responses of PMO-Treated Mice Following Survival of Ebola Virus Infection
###end title 104
###begin p 105
###xml 100 101 100 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 473 474 469 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 502 503 494 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 24 28 <span type="species:ncbi:10090">mice</span>
###xml 59 63 <span type="species:ncbi:205488">EBOV</span>
###xml 83 87 <span type="species:ncbi:205488">EBOV</span>
###xml 155 159 <span type="species:ncbi:205488">EBOV</span>
###xml 202 206 <span type="species:ncbi:205488">EBOV</span>
###xml 638 642 <span type="species:ncbi:205488">EBOV</span>
###xml 683 687 <span type="species:ncbi:10090">mice</span>
(A) PMO-treated C57BL/6 mice that have previously survived EBOV infection generate EBOV-specific CD8+ responses. Pooled splenocytes from three PMO-treated EBOV survivors were restimulated in vitro with EBOV-specific VP35 or NP peptides, an irrelevant Lassa NP peptide as a negative control, or PMA/ionomycin as a positive control. The stimulated cells were stained after for 4 h in culture with anti-CD44-FITC, anti-IFN-gamma-PE, and anti-CD8-Cy-Chrome. The percent of CD44+, IFN-gamma+ cells among CD8+ lymphocytes is indicated in the upper right quadrant of each plot. These data are representative of several experiments examining the EBOV-specific T cell epitopes in PMO-treated mice after challenge.
###end p 105
###begin p 106
###xml 21 25 <span type="species:ncbi:205488">EBOV</span>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
###xml 125 129 <span type="species:ncbi:10090">mice</span>
###xml 249 253 <span type="species:ncbi:10090">mice</span>
###xml 290 294 <span type="species:ncbi:205488">EBOV</span>
###xml 372 376 <span type="species:ncbi:10090">mice</span>
(B) Total serum anti-EBOV antibodies were measured in surviving mice prior to or 4 wk following treatment and challenge. PMO mice were treated with the combination of PMOs 24 hand 4 h before challenge, and their antibody responses are compared with mice treated with Ebola VLPs 24 h before EBOV infection. The results are depicted as the endpoint titers of the individual mice (filled circles). The horizontal line in each column represents the geometric mean titer of the group.
###end p 106
###begin p 107
###xml 266 267 266 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 4 8 <span type="species:ncbi:10090">Mice</span>
###xml 34 38 <span type="species:ncbi:205488">EBOV</span>
###xml 109 114 <span type="species:ncbi:10090">mouse</span>
###xml 123 134 <span type="species:ncbi:205488">Ebola virus</span>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 260 264 <span type="species:ncbi:10090">mice</span>
(C) Mice that previously survived EBOV challenge following PMO treatment were rechallenged with 1,000 pfu of mouse-adapted Ebola virus 4 wk after the initial challenge. Results are plotted as percent survival for the PMO-treated mice (black) and naive control mice (n = 10 per group).
###end p 107
###begin title 108
###xml 20 24 <span type="species:ncbi:9823">Pigs</span>
Treatment of Guinea Pigs with Antisense PMOs Increases Survival Following Lethal Ebola Virus Infection
###end title 108
###begin p 109
###xml 21 22 21 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 8 19 <span type="species:ncbi:10141">guinea pigs</span>
###xml 206 217 <span type="species:ncbi:10141">guinea pigs</span>
###xml 261 272 <span type="species:ncbi:10141">guinea pigs</span>
###xml 321 325 <span type="species:ncbi:205488">EBOV</span>
Hartley guinea pigs (n = 6) weighing 400-500 g each were treated intraperitoneally with 10 mg each of VP24, VP35, and L PMO in PBS at -24 (triangle), +24 (circle), or +96 (square) h post challenge. Control guinea pigs were injected with PBS only (diamond). The guinea pigs were infected subcutaneously with ~1,000 pfu of EBOV and monitored for illness for 21 d.
###end p 109
###begin p 110
(A) The data are presented as percent survival for each group.
###end p 110
###begin p 111
###xml 33 44 <span type="species:ncbi:10141">guinea pigs</span>
###xml 125 136 <span type="species:ncbi:10141">guinea pigs</span>
(B) Viral titers in the serum of guinea pigs at 7 d post challenge (dpc). The data are presented as the titers of individual guinea pigs treated with PMOs at -24, +24, or +96 h post challenge or PBS only and the mean viral titer for each group (horizontal line). Animals which survived are represented by open symbols and those that succumbed to disease are represented by filled symbols.
###end p 111
###begin title 112
Treatment of Rhesus Macaques with Antisense PMOs Provide Protection against Lethal Ebola Virus Infection
###end title 112
###begin p 113
###xml 76 87 <span type="species:ncbi:205488">Ebola virus</span>
(A) Treatment schedule for proof-of-concept trial using PMO to treat lethal Ebola virus infection in nonhuman primates.
###end p 113
###begin p 114
###xml 132 133 106 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 164 165 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 51 55 <span type="species:ncbi:205488">EBOV</span>
(B) Survival following infection with 1,000 pfu of EBOV in monkeys treated with a combination of PMOs (blacksquare, square, filled, n = 4) or untreated monkeys (o, n = 3). The arrows indicate the time of death of each PMO-treated monkey.
###end p 114
###begin p 115
(C-E) Viral titers (C), platelet counts (D), or alkaline phosphatase levels (E) in the blood of the PMO-treated monkeys [0646 (diamond), 1438 (black triangle), 1496 (x), 1510 (blacksquare, square, filled)] or a representative untreated monkey (o).
###end p 115
###begin p 116
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. KLW, DLS, GGO, DKN, WDP, RB, DAS, PLI, and SB conceived and designed the experiments. KLW, DLS, GGO, DKN, WDP, RB, DAS, and SB performed the experiments. KLW, DLS, GGO, DKN, WDP, RB, DAS, MJA, PLI, and SB analyzed the data. PLI and SB contributed reagents/materials/analysis tools. KLW, MJA, DAS, and SB wrote the paper.
###end p 116
###begin p 117
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. RB, DAS, and PLI have financial interest in AVI BioPharma, the company that supplied the PMO compounds for these studies.
###end p 117
###begin p 118
###xml 121 132 <span type="species:ncbi:205488">Ebola virus</span>
Citation: Warfield KL, Swenson DL, Olinger GG, Nichols DK, Pratt WD, et al. (2006) Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2(1): e1.
###end p 118

